We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Plus of course everything else that has a very positive chance of doing well
The 6m tests is the combined total for 200 and 350. It’s important to point out that ODX themselves are hoping for 4m tests in 3-5 years which would still be transformative if we achieved that number. Basically ODX say the total market for POC tests is 6m tests a year and they are (perhaps conservatively) hoping to capture 66% of that market. Finncap are essentially saying they’ll end up with the whole market.
Is the six million for 350 tests only or 200s also? What’s the expected total per year ?
They’ll be quite a lot of money already made from the lows so some are getting out after doing quite well.
Zak Mir will know nothing about Omega apart from what he read today and will only attract more day traders I'm afraid. But they wont stay around for long....
Hi up, Traders are not at all interested in fundamentals. Its of no interest to them. They make a profit and they're out. We may actually see more traders turn up here than usual now Zak Mir has covered 'Omega Dynamics' (yes that's actually what he called us) for the first time. FWIW he (ZM) was very bullish about the SP pattern. Mind you he's wrong quite a lot lol.
Have a good weekend and let's see what next week brings.
Dibs
If Fincaps analysis is correct re 10p per share per 500/- then we are all in for a very pleasant surprise. As I mentioned on the other board im a bit surprised with the amount of people selling today, but you are right people do tend to sell on news. Surely they must be aware that we are due further news which could really transform the share price ??????
Hi Rivaldo, thanks for the informative post. Am I interpreting their valuation correctly as 125 pence per share based on 6 million CD4 tests sold Per annum?
Finncap have retained their 25p target for the moment.
Their current forecast to March'20 only incorporates a total 120k CD4 tests, whereas ODX have already received orders from Nigeria alone for 250k tests and indicated in December that 200k orders could be shipped by the end of March.
At $5 per test this could therefore decent upside to forecasts if ODX can ship 200k or more before April.
Worth reiterating Finncap's closing comment as before:
"Given the potential annual demand for c.6m VISITECT CD4 tests, profits, earnings and target price are very sensitive to supply. For every additional 0.5m CD4 tests sold annually, our target price would rise by c.£15m or 10p per share."